Resistance to therapy caused by intragenic deletion in BRCA2
about
P1343
Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repairFIGNL1-containing protein complex is required for efficient homologous recombination repairAPRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancerStructural basis for recruitment of BRCA2 by PALB2PALB2 regulates recombinational repair through chromatin association and oligomerization6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistanceFailure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitroSusceptibility pathways in Fanconi's anemia and breast cancerBRCAness: finding the Achilles heel in ovarian cancerHow the fanconi anemia pathway guards the genomeHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsCytotoxic and targeted therapy for hereditary cancersTargeting DNA Replication Stress for Cancer TherapyTrial watch - inhibiting PARP enzymes for anticancer therapyThe Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsSuccesses and Challenges of PARP Inhibitors in Cancer TherapyOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerPARP inhibitors in the management of breast cancer: current data and future prospectsProfile of veliparib and its potential in the treatment of solid tumorsThe expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2From integrative genomics to therapeutic targetsSystems biology of cisplatin resistance: past, present and futureTumour heterogeneity and the evolution of polyclonal drug resistanceBreast cancer intra-tumor heterogeneityGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersTargeting DNA damage response in cancer therapyPARP inhibitors and moreClonal evolution in hematological malignancies and therapeutic implicationsA phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - AnFine tuning chemotherapy to match BRCA1 statusGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasGenome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.Role of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentHomologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteinsMolding BRCA2 function through its interacting partners
P2860
Q21145054-96CAF6D8-EBD6-4D90-BEC8-958CA16430AAQ24294857-834F796D-4FBC-44E5-AE65-7AA02511EEFBQ24304176-FA89455C-A65A-47DE-BA3C-31BD535B21C5Q24315745-5D915178-CEB9-4564-BB1E-DBB359690F26Q24322952-7FA5C327-B7FE-447D-9F74-3942CCBBDF9FQ24599364-D5D748E4-447D-44B4-9BC3-1997F480CA3FQ24615499-8260ECF4-710E-4637-8486-DA84D6619777Q24628760-C46736D7-ABE8-42CD-9049-462B2BFA6A70Q24630872-7878C095-D488-4E44-85D6-7854A2F748CBQ24634556-A07199D3-0D77-4BAF-ABBB-83C0C64AF10BQ24644255-40B1C347-6154-44D7-8A4A-EA1881596608Q26739366-398D5D3E-C381-40CF-9FA2-48BC9CD1C82DQ26739923-0816B8C4-8C30-4B5D-87A6-F65644088F8DQ26745673-7C094077-E719-4072-96B5-EAA5D5CC17C6Q26765247-1364E2A8-5185-4C4F-A4FC-B413B6BB5601Q26777131-67308942-4A4B-44C9-9481-8286311EA076Q26777846-B0306F13-C074-4B3C-B00E-9920B33C5A26Q26780387-97F03B66-8621-44E8-B3FD-B202D7B089C2Q26783551-60D2B9A2-5B7F-4692-BFED-CD02AD30FF23Q26798352-84C42BDE-1870-4B4D-87F7-2997D6B65421Q26801272-10A1DD90-451D-4D67-9E2A-571EE38B8203Q26851138-9DF441C5-1EFC-4701-B8FE-2AC74C41AB76Q26862726-1CB11A90-A427-40DF-B557-B5A6EB8B262CQ26863585-2343632E-77B6-41B0-93D2-1E9D2514CEBCQ26866803-54E67479-E69C-43CE-9664-0AFBEEC892BFQ27000086-A5DAE9FA-205F-4A70-A6E1-0398A9AFF62FQ27006938-E37C091C-C406-4A27-8232-426AE4B2941EQ27023204-8464B9C3-70E9-45DA-92CD-4E32B97FB20AQ27027014-AD473887-5629-4F9D-B8C9-7391AB34CF10Q27027655-CF0C2AA6-2030-4B76-B8B8-ECC9E163F849Q27302763-5A6C5BBF-A3B5-4F9C-97C6-DE6F388A98ACQ27694529-CF4B58F3-3B3E-439F-9E38-88657A20B7BBQ27852671-594C5F2A-7B31-49DD-AF00-17353BBB5164Q27852678-AD671CBF-9E83-457B-9029-D899503F2CBCQ28069963-6236CEA9-C3B1-461F-856D-CF57910F7760Q28071345-F6A9CD3F-27D9-4AC4-A8DE-EDC246AEF7A0Q28071541-EF544761-A1A3-47D1-9FFD-2DBD2C1A8E05Q28075761-E599EE6B-8C04-4976-8B05-9400DCCDEEDAQ28085364-FA72C82F-949C-4860-8CAC-53178E690F18Q28085603-3F0D581A-93BB-4D3B-A02F-33A41AEC01AA
P2860
Resistance to therapy caused by intragenic deletion in BRCA2
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Resistance to therapy caused by intragenic deletion in BRCA2
@ast
Resistance to therapy caused by intragenic deletion in BRCA2
@en
Resistance to therapy caused by intragenic deletion in BRCA2
@nl
type
label
Resistance to therapy caused by intragenic deletion in BRCA2
@ast
Resistance to therapy caused by intragenic deletion in BRCA2
@en
Resistance to therapy caused by intragenic deletion in BRCA2
@nl
prefLabel
Resistance to therapy caused by intragenic deletion in BRCA2
@ast
Resistance to therapy caused by intragenic deletion in BRCA2
@en
Resistance to therapy caused by intragenic deletion in BRCA2
@nl
P2093
P50
P3181
P356
P1433
P1476
Resistance to therapy caused by intragenic deletion in BRCA2
@en
P2093
Douglas A Levine
Rachel Brough
Radost Vatcheva
Stacey L Edwards
P2888
P304
P3181
P356
10.1038/NATURE06548
P407
P577
2008-02-28T00:00:00Z
P6179
1040539424